Weekly Recap | ImmunityBio +21.86%, clearing key resistance
I'm LongbridgeAI, I can summarize articles.ImmunityBio (IBRX) gained 21.86% this week to close at $10.285, while the S&P 500 slipped 0.27%. That puts the stock about 22.13 percentage points ahead of the benchmark. The week built higher day by day, from an open of $8.39 on Monday to an intraday high of $10.55 on Friday, with a range of 27.29%. Average daily volume was roughly double its median.
The Week
ImmunityBio (IBRX) gained 21.86% this week to close at $10.285, while the S&P 500 slipped 0.27%. That puts the stock about 22.13 percentage points ahead of the benchmark. The week built higher day by day, from an open of $8.39 on Monday to an intraday high of $10.55 on Friday, with a range of 27.29%. Average daily volume was roughly double its median.
Key Events
There were no major company filings during the week, so the story centred on insider buying and a technical breakout. On 29 September, reports pointing to insider purchases accompanied a modest climb. On 30 September, the stock rose 11.15% and cleared a key resistance level on volume of 27.3m shares. On 2 October, ImmunityBio attended the Thoracic Rare Cancer Symposium (THORACS) and the share price gained 9.64% on the day, with overnight chatter also linking IBRX to retail interest in Moderna’s rally.
Analyst Ratings
Three brokers currently cover the stock: two rate it buy and one rates it overweight, with no hold, underweight or sell ratings. The consensus rating is strong buy and the consensus target is $13, about 26.4% above the last price of $10.285. Targets range from $12 to $15, so dispersion is modest. Within the biotechnology industry, the stock ranks 372nd out of 507 names on ratings.
The Week Ahead
On 5 October, the US releases the final S&P Global services PMI and the ISM non-manufacturing PMI. Trade figures follow on 6 October, and EIA weekly crude inventories land on 7 October. The stock itself has no scheduled earnings in the coming week, so the focus shifts to how macro data shapes risk appetite for growth names.
In Short
The rally this week came alongside a technical breakout and a conference appearance, and broker ratings lean constructive with a consensus target above spot. Yet the company remains loss-making, and the latest daily flow shows large and medium lots were net sellers. The question ahead is whether macro prints keep pressure on risk assets and whether IBRX can hold current levels without fresh company-specific news.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.